next
influenza
pandem
may
immin
antivir
agent
vaccin
unavail
peopl
countri
need
determin
whether
agent
could
offer
clinic
benefit
influenza
associ
increas
acut
cardiovascular
diseas
influenza
virus
induc
proinflammatori
cytokin
statin
cardioprotect
antiinflammatori
immunomodulatori
effect
thu
might
benefit
patient
influenza
hypothesi
evalu
use
administr
databas
search
reduc
rate
hospit
death
due
influenzarel
condit
among
peopl
take
statin
studi
follow
laboratori
studi
statin
anim
cellbas
model
influenza
viru
infect
later
clinic
trial
posit
result
studi
would
provid
physician
countri
someth
offer
patient
treatment
prophylaxi
pandem
influenza
gener
statin
wide
distribut
inexpens
might
agent
could
alter
cours
global
pandem
influenza
expert
health
offici
throughout
world
extrem
concern
global
spread
avian
influenza
possibl
could
lead
next
pandem
pandem
like
pandem
occur
today
would
kill
million
peopl
worldwid
casefat
rate
associ
next
pandem
like
associ
human
case
influenza
recent
seen
southeast
asia
would
kill
even
peopl
specul
like
may
seem
farfetch
avian
influenza
virus
caus
devast
outbreak
diseas
mammalian
speci
man
earli
exampl
avian
influenza
epidem
kill
harbor
seal
live
along
north
atlant
coast
predict
whether
next
influenza
pandem
mild
like
pandem
moder
like
pandem
sever
like
pandem
overwhelmingli
catastroph
certain
howev
occur
sooner
later
happen
limit
suppli
antivir
agent
antivir
resist
might
compromis
use
influenza
virus
moreov
wait
mani
month
limit
suppli
vaccin
becom
avail
influenza
pandem
immin
prospect
obtain
adequ
suppli
antigenspar
pandem
vaccin
becom
increasingli
remot
practic
speak
peopl
world
littl
access
antivir
agent
vaccin
reason
need
determin
whether
current
avail
agent
could
use
treatment
prophylaxi
pandem
influenza
influenza
viru
infect
associ
increas
acut
cardiovascular
cerebrovascular
hereaft
call
cardiovascular
diseas
winterseason
mortal
associ
event
greater
ascrib
influenzarel
pneumonia
respiratori
condit
influenza
prevent
vaccin
hospit
death
due
influenzarel
cardiovascular
diseas
reduc
influenza
virus
potent
induc
mani
biolog
respons
mediat
make
innat
immun
system
experiment
natur
occur
human
influenza
viru
infect
increas
serum
level
sever
proinflammatori
cytokin
eg
tnfa
posit
correl
symptom
clinic
ill
experiment
model
human
influenza
viru
infect
virus
shown
potent
induc
tnfa
virus
avian
influenza
virus
caus
fatal
diseas
human
except
potent
induc
proinflammatori
cytokin
cytokin
dysregul
regard
major
contributor
sever
pathophysiolog
chang
seen
human
diseas
caus
avian
pandem
influenza
virus
inflamm
play
import
role
pathogenesi
stage
cardiovascular
diseas
proinflammatori
cytokin
reduc
benefici
effect
endotheli
nitric
oxid
synthas
thrombomodulin
help
maintain
normal
blood
flow
also
increas
express
surfac
adhes
molecul
eg
vascular
cell
adhes
recruit
leukocyt
vessel
wall
leukocyt
turn
elabor
proinflammatori
factor
eg
creactiv
protein
solubl
ligand
set
stage
acut
intravascular
thrombosi
event
increas
level
sever
cytokin
demonstr
patient
serum
sampl
clinic
benefit
statin
coenzym
reductas
inhibitor
patient
cardiovascular
diseas
firmli
establish
recent
metaanalysi
individu
enrol
random
control
trial
show
period
statin
associ
reduct
major
cardiovascular
event
includ
reduct
mortal
associ
coronari
event
reduct
fatal
nonfat
stroke
level
protect
observ
statin
reduc
level
lowdens
lipoprotein
cholesterol
also
wide
varieti
antiinflammatori
immunomodulatori
effect
statin
improv
endotheli
cell
function
decreas
cellular
adhes
decreas
vascular
cell
adhes
thrombosi
decreas
tissu
factor
increas
vasoreact
increas
endotheli
nitric
oxid
synthas
affect
immun
inflammatori
cell
reduc
monocyt
macrophag
recruit
express
numer
cytokin
chemokin
eg
tnfa
ifng
rant
regul
activ
normal
cell
express
secret
solubl
ligand
also
inhibit
smooth
muscl
cell
prolifer
platelet
hyperreact
molecular
level
statin
interact
synthesi
isoprenyl
protein
serv
lipid
attach
small
guanosin
triphosphatebind
ra
raslik
eg
rho
rac
protein
action
improv
vascular
function
increas
endotheli
nitric
oxid
synthas
decreas
leukocyt
adhes
fibrinolyt
activ
addit
affect
nuclear
event
regul
gene
express
cell
function
proinflammatori
stimuli
caus
rho
rholik
protein
induc
nuclear
factorkb
nfkb
transloc
cell
nucleu
induc
express
target
gene
includ
sever
cytokin
statin
limit
activ
statin
also
reduc
express
regulatori
protein
compos
activ
protein
complex
induc
express
nuclear
factor
eg
kruppellik
exert
broad
effect
endotheli
cell
function
increas
endotheli
nitric
oxid
synthas
decreas
vascular
cell
adhes
activ
counterbal
nfkb
statinmedi
induct
endotheli
nitric
oxid
synthas
thrombomodulin
depend
kruppellik
larg
bodi
evid
suggest
longterm
cardiovascular
benefit
statin
associ
antiinflammatori
immunomodulatori
effect
howev
statin
also
induc
remark
shortterm
improv
cardiovascular
function
exampl
use
shortterm
lowdos
simvastatin
treatment
patient
nonischem
dilat
cardiomyopathi
result
clinic
improv
associ
substanti
reduct
serum
level
sever
inflammatori
mediat
includ
tnfa
antiinflammatori
effect
pravastatin
coronari
endotheli
dysfunct
simvastatin
creactiv
protein
level
demonstr
patient
even
administr
singl
dose
moreov
epidemiolog
studi
patient
acut
myocardi
infarct
shown
continu
receiv
newli
receiv
statin
within
h
hospit
reduct
mortal
compar
patient
treat
shortterm
effect
statin
might
import
implic
manag
acut
lifethreaten
event
associ
inflamm
addit
effect
cardiovascular
diseas
grow
evid
statin
could
benefici
treatment
patient
lifethreaten
infect
associ
cytokin
dysregul
exampl
infant
bacteri
sepsi
serum
level
sever
proinflammatori
cytokin
higher
infant
cultureneg
sepsi
syndrom
level
highest
infant
die
adult
sepsi
depress
myocardi
contractil
associ
increas
level
sever
proinflammatori
cytokin
serum
sampl
obtain
patient
activ
transcript
factor
induc
human
fetal
cardiac
myocyt
apoptosi
experiment
studi
suggest
statin
favor
alter
cours
bacteri
sepsi
murin
model
acut
bacteri
sepsi
cecal
ligat
punctur
without
subsequ
administr
tibiot
prophylaxi
treatment
simvastatin
dramat
preserv
cardiac
hemodynam
function
significantli
prolong
surviv
addit
clinic
report
suggest
statin
benefit
patient
acut
bacteri
sepsi
tabl
first
studi
includ
patient
hospit
gramneg
staphylococcu
aureu
bacteremia
second
studi
includ
patient
hospit
presum
document
acut
bacteri
infect
third
studi
includ
patient
hospit
bacteri
sepsi
remark
statin
treatment
continu
hospit
rate
death
attribut
bacteremia
reduc
first
studi
third
studi
addit
populationbas
nest
casecontrol
studi
elderli
patient
discharg
hospit
acut
cardiovascular
event
show
risk
subsequ
hospit
sepsi
fatal
sepsi
lower
statintr
patient
untreat
control
patient
tabl
anoth
populationbas
studi
find
benefici
effect
statin
sepsisassoci
mortal
number
statintr
patient
small
ci
around
point
estim
broad
tabl
mani
physician
begun
ask
whether
treatment
sepsi
includ
statin
mechan
statin
exert
benefici
effect
patient
bacteremia
sepsi
well
understood
anim
model
acut
lipopolysaccharideinduc
sepsi
similar
endotoxemia
bacteri
sepsi
shown
varieti
inflammatori
mediat
implic
fatal
diseas
nonetheless
mani
treatment
intervent
target
specif
abnorm
suggest
anim
studi
eg
tnfa
efficaci
test
clinic
trial
human
date
lowdos
corticosteroid
activ
protein
c
shown
benefit
patient
sever
sepsi
howev
sever
newer
therapeut
target
consid
includ
tolllik
receptor
highmobl
group
box
protein
macrophag
migrat
inhibitori
factor
complement
receptor
inhibitor
apoptosi
statin
effect
sever
target
cytokin
also
act
inflammatori
mediat
acut
lung
injuri
shown
experiment
clinic
studi
recent
report
simvastatin
dramat
reduc
respons
human
pulmonari
arteri
endotheli
cell
thrombininduc
endotheli
barrier
cytoskelet
dysfunct
effect
requir
gene
express
protein
synthesi
simvastatin
also
induc
pronounc
endotheli
barrier
protect
murin
model
acut
lung
injuri
caus
intratrach
administr
lipopolysaccharid
model
simvastatin
significantli
alter
lipopolysaccharidemedi
express
sever
gene
associ
inflammatori
chang
eg
tolllik
receptor
anoth
model
acut
lung
injuri
rat
intestin
ischemia
reperfus
pretreat
simvastatin
associ
reduc
leukocyt
infiltr
lung
tissu
decreas
product
free
oxygen
radic
reduc
sever
acut
lung
injuri
clinic
studi
healthi
elderli
peopl
shown
elev
level
proinflammatori
cytokin
tnfa
increas
risk
admit
hospit
later
communityacquir
pneumonia
moreov
among
hospit
patient
pneumonia
elev
proinflammatori
cytokin
increas
risk
develop
septic
shock
recent
retrospect
studi
patient
communityacquir
pneumonia
show
mortal
reduc
among
previous
take
statin
tabl
antiinflammatori
immunomodulatori
effect
statin
host
respons
acut
lung
injuri
becom
increasingli
evid
given
clinic
associ
influenza
cardiovascular
diseas
cytokinemedi
inflammatori
chang
associ
possibl
benefit
statin
evid
cardiovascular
diseas
bacteremia
sepsi
pneumonia
might
also
extend
patient
influenza
date
report
publish
describ
direct
effect
statin
molecular
clinic
pathophysiolog
profil
experiment
clinic
influenza
viru
infect
nonetheless
find
outlin
suggest
possibl
treatment
prophylaxi
statin
might
alter
clinic
cours
outcom
interpandem
pandem
influenza
hypothesi
could
evalu
sever
way
initi
direct
probabl
effici
approach
would
look
epidemiolog
signal
protect
provid
statin
influenzarel
event
popul
interpandem
year
exampl
cardiologist
could
evalu
occurr
event
treat
control
subject
particip
larg
prospect
random
control
trial
statin
unfortun
studi
might
conclus
patient
enrol
trial
younger
rather
older
adult
experienc
rel
hospit
death
due
respiratori
condit
altern
investig
could
follow
epidemiolog
model
statinssepsi
studi
mention
undertak
retrospect
cohort
casecontrol
studi
effect
statin
peopl
whose
health
care
medic
treatment
document
larg
administr
databas
primari
goal
studi
would
see
whether
differ
untreat
statintr
subject
regard
rate
influenzarel
hospit
death
especi
due
pneumonia
influenza
respiratori
condit
outcom
would
need
evalu
outsid
influenza
season
care
adjust
confound
variabl
includ
influenza
vaccin
would
essenti
hope
epidemiolog
studi
would
show
benefit
statin
influenzarel
outcom
howev
might
show
statin
treatment
could
harm
exampl
statin
could
impair
host
defens
lead
increas
secondari
bacteri
pneumonia
could
downregul
cytokin
lead
uncontrol
viru
replic
increas
mortal
altern
discontinu
statin
treatment
could
quickli
follow
clinic
deterior
shown
rapid
loss
statininduc
antiinflammatori
immunomodulatori
effect
experiment
model
endotheli
dysfunct
stroke
whatev
epidemiolog
find
could
use
gener
hypothes
wide
rang
laboratori
clinic
studi
two
epidemiolog
studi
undertaken
test
statininfluenza
hypothesi
one
studi
conduct
investig
netherland
use
larg
gener
practic
administr
databas
conduct
swiss
investig
use
unit
kingdom
gener
practic
research
databas
swiss
investig
recent
complet
populationbas
nest
casecontrol
studi
pneumonia
r
g
schlienger
c
meier
person
commun
studi
case
occur
throughout
year
occur
influenza
season
found
peopl
current
take
statin
defin
statin
prescrib
within
day
date
onset
pneumonia
statist
signific
reduc
risk
pneumoniaassoci
mortal
lower
quit
statist
signific
risk
hospit
pneumonia
surviv
protect
shown
taken
statin
past
defin
statin
prescrib
day
date
onset
pneumonia
current
take
shown
taken
control
medic
time
preliminari
find
dutch
epidemiolog
studi
also
suggest
statin
treatment
associ
reduct
influenzarel
pneumonia
acut
myocardi
infarct
stroke
result
obtain
epidemiolog
studi
mention
suggest
patient
treat
statin
prevent
cardiovascular
diseas
also
protect
respiratori
diseas
often
associ
influenza
given
limit
data
avail
investig
studi
could
determin
whether
statin
treatment
continu
hospit
admiss
although
mani
instanc
probabl
epidemiolog
signal
protect
obtain
swiss
dutch
studi
need
confirm
populationbas
studi
nonetheless
togeth
clinic
studi
summar
tabl
provid
enough
evid
justifi
undertak
laboratori
studi
statin
treatment
prophylaxi
anim
model
influenza
caus
interpandem
avian
pandemiclik
virus
challeng
virus
includ
relat
reassort
differ
degre
virul
wherev
possibl
studi
evalu
effect
statin
cellular
molecular
manifest
diseas
compar
result
correspond
gene
express
profil
special
attent
given
effect
statin
secondari
bacteri
pneumonia
result
studi
need
cautious
interpret
indic
experi
gain
interpret
conflict
result
anim
model
human
studi
therapeut
intervent
sepsi
anim
studi
influenza
indic
statin
protect
investig
explor
molecular
effect
statin
influenza
virusinfect
cell
cholesterol
synthesi
essenti
normal
function
cell
membran
especi
lipid
raft
cholesterol
also
essenti
influenza
viru
assembl
bud
raftderiv
microdomain
viru
infect
cell
experiment
studi
mice
shown
tolllik
receptor
locat
endosom
compart
cell
recogn
singlestrand
influenza
viru
rna
recogn
tolllik
receptor
recruit
sever
adaptor
molecul
eg
myeloid
differenti
protein
seri
signal
step
lead
transloc
nfkb
nucleu
essenti
event
establish
influenza
viru
infect
pathway
control
gene
express
sever
proinflammatori
cytokin
chemokin
eg
tnfa
type
interferon
plasmacytoid
dendrit
cell
matur
antivir
immun
mani
intracellular
signal
cascad
identifi
cell
infect
influenza
viru
one
import
intracellular
signal
pathway
involv
influenza
virusinduc
caspas
activ
subsequ
apoptosi
caspas
activ
essenti
influenza
viru
replic
apoptosi
thought
respons
induct
lymphocyt
deplet
promin
human
influenza
viru
infect
downregul
proinflammatori
cytokin
overal
host
benefit
apoptosi
howev
still
uncertain
alreadi
known
statin
potenti
affect
mani
molecular
pathway
influenza
virusinfect
cell
clinic
investig
also
begin
gather
inform
cytokin
profil
level
potenti
immunomodulatori
molecul
eg
highmobl
group
box
protein
hyaluron
degrad
product
patient
season
avian
influenza
give
attent
establish
correl
diseas
sever
prognosi
eventu
might
begin
plan
clinic
trial
statin
treatment
prophylaxi
studi
statin
safeti
well
statin
efficaci
children
would
especi
import
physician
care
patient
lifethreaten
avian
infect
could
even
consid
treat
patient
statin
compassion
basi
statin
might
medic
use
treatment
prophylaxi
pandem
influenza
epidemiologist
laboratori
investig
clinician
look
evid
exist
agent
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
aldosteron
antagonist
phosphodiesteras
inhibitor
might
benefici
either
alon
combin
ideal
agent
gener
produc
wide
avail
develop
countri
inexpens
research
statin
agent
might
also
relev
seriou
viru
diseas
sever
acut
respiratori
syndrom
hivaid
next
pandem
arriv
physician
live
countri
without
antivir
stockpil
vaccin
compani
littl
noth
offer
patient
epidemiolog
laboratori
clinic
studi
confirm
benefit
statin
treatment
influenza
physician
everywher
someth
offer
patient
pandem
statin
alreadi
wide
distribut
throughout
world
use
treat
million
peopl
yearround
basi
moreov
patent
sever
statin
expir
year
two
sever
alreadi
produc
gener
develop
countri
cost
advantag
statin
compar
exist
antivir
agent
remark
current
unit
state
cours
antivir
agent
oseltamivir
cost
wherea
cours
gener
simvastatin
cost
littl
develop
countri
cost
advantag
gener
statin
even
greater
scientif
rational
consid
statin
treatment
prophylaxi
pandem
influenza
persuas
public
health
rational
overwhelmingli
compel
given
low
cost
safeti
worldwid
avail
gener
statin
could
becom
crucial
import
confront
next
pandem
could
greatli
reduc
dispar
otherwis
separ
develop
develop
countri
could
becom
current
avail
agent
alter
cours
otherwis
might
becom
unpreced
global
health
crisi
public
health
reason
alon
research
agenda
outlin
present
report
one
afford
undertak
must
great
sens
urgenc
potenti
conflict
interest
dsf
receiv
travel
support
modest
honoraria
sanofi
pasteur
intern
lectur
pandem
influenza
influenza
vaccin
deliv
scientif
meet
meet
per
year
decemb
decemb
work
parttim
consult
influenza
vaccin
suppli
intern
task
forc
instrument
organ
novemb
work
director
medic
affair
aventi
pasteur
msd
european
vaccin
compani
current
consult
agreement
financi
arrang
compani
institut
own
stock
vaccin
pharmaceut
compani
